clinical trial · NCT07412613
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso·phase3·recruiting·n = 386
Resectable Colon CancerMSI-H/dMMR Colorectal CancerCadonilimab (AK104)OxaliplatinCapecitabine5- FluorouracilCalcium Folinate
brief summary
This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant/adjuvant treatment of AK104 (Cadonilimab) versus adjuvant chemotherapy in patients with resectable MSI-H/dMMR colon cancer.
started
Apr 15, 2026
primary completion
Jun 15, 2030
completion
Mar 15, 2031
last updated
Apr 22, 2026
official title
A Randomized, Open-label, Controlled, Multicenter Phase 3 Clinical Trial of AK104 for Neoadjuvant/Adjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol